ESTRO 2023 - Abstract Book

S912

Digital Posters

ESTRO 2023

For HFRST, the median mean dose to the GTV was 32.27 Gy (19.82-50.76), with a median prescription isodose of 56.4 % (48.6-68), and a median gradient of 2.81(2.45-4). Patients at the HFSRT group achieved a local control rate (LCR) of 100% at 1 and at 2 years, whereas those who received CRT achieved LCR of 100% and 97% at1 and at 2 years, respectively. Progression-free survival (PFS) was not significantly different between the two techniques (HR=2. 5, 95%CI (0. 26-24), p=0.4). In the multivariate analysis, there were no significant correlations between the independent variables (dose, number of surgeries before radiotherapy, sinus extension, GTV size and secretory status) and local control at 1 year, and two years.